Vestmark Advisory Solutions’s GSK GSK Stock Holding History

Vestmark Advisory Solutions’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.25M	Sell	42,977 -39,485	-48%	-$2.09M	0.02%	663
2026 Q1	$4.55M	Sell	82,462 -37,439	-31%	-$2.03M	0.05%	371
2025 Q4	$5.88M	Buy	119,901 +58,354	+95%	+$2.72M	0.08%	260
2025 Q3	$2.66M	Sell	61,547 -6,415	-9%	-$251K	0.05%	354
2025 Q2	$2.61M	Sell	67,962 -45,026	-40%	-$1.72M	0.04%	330
2025 Q1	$4.38M	Buy	112,988 +63,154	+127%	+$2.31M	0.11%	228
2024 Q4	$1.69M	Buy	49,834 +10,310	+26%	+$371K	0.06%	278
2024 Q3	$1.62M	Buy	39,524 +1,186	+3%	+$48.5K	0.06%	262
2024 Q2	$1.48M	Buy	38,338 +961	+3%	+$40.4K	0.06%	275
2024 Q1	$1.6M	Buy	37,377 +505	+1%	+$20.8K	0.07%	264
2023 Q4	$1.37M	Sell	36,872 -1,184	-3%	-$42.5K	0.07%	260
2023 Q3	$1.38M	Sell	38,056 -11,950	-24%	-$424K	0.1%	215
2023 Q2	$1.78M	Buy	50,006 +7,484	+18%	+$268K	0.07%	338
2023 Q1	$1.51M	Buy	42,522 +15,122	+55%	+$529K	0.07%	340
2022 Q4	$963K	Sell	27,400 -1,339	-5%	-$44.6K	0.05%	427
2022 Q3	$846K	Buy	28,739 +8,285	+41%	+$314K	0.05%	421
2022 Q2	$1.11M	Buy	20,454 +616	+3%	+$34K	0.06%	342
2022 Q1	$1.08M	Buy	19,838 +10,185	+106%	+$553K	0.06%	338
2021 Q4	$532K	Hold	9,653	–	–	0.03%	527
2021 Q3	$461K	Buy	9,653 +47	+0.5%	+$2.36K	0.03%	516
2021 Q2	$478K	Sell	9,606 -376	-4%	-$18.1K	0.03%	489
2021 Q1	$445K	Sell	9,982 -2,952	-23%	-$134K	0.04%	468
2020 Q4	$595K	Sell	12,934 -4,837	-27%	-$222K	0.07%	318
2020 Q3	$836K	Sell	17,771 -1,975	-10%	-$99K	0.11%	246
2020 Q2	$1.01M	Sell	19,746 -667	-3%	-$34.2K	0.16%	181
2020 Q1	$967K	Sell	20,413 -4,102	-17%	-$219K	0.19%	163
2019 Q4	$1.44M	Sell	24,515 -1,137	-4%	-$63.2K	0.3%	120
2019 Q3	$1.37M	Sell	25,652 -1,653	-6%	-$85K	0.22%	140
2019 Q2	$1.37M	Buy	27,305 +1,407	+5%	+$70.6K	0.23%	134
2019 Q1	$1.35M	Buy	+25,898	New	+$1.29M	0.24%	126

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vestmark Advisory Solutions's GSK Position: Q2 2026 in Review

Vestmark Advisory Solutions reduced its GSK (GSK) stake by 48% in Q2 2026, selling an estimated $2.09M and leaving 42,977 shares worth $2.25M. The position accounts for 0.02% of the portfolio, ranked #663.

Vestmark Advisory Solutions first reported a position in GSK in Q1 2019 and has held it in 30 quarters since. The position peaked at $5.88M in Q4 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Vestmark Advisory Solutions held 42,977 shares of GSK worth $2.25M as of Q2 2026.
Vestmark Advisory Solutions sold 39,485 GSK shares in Q2 2026, an estimated $2.09M.
GSK made up 0.02% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #663 holding.
Vestmark Advisory Solutions first reported a position in GSK in Q1 2019 and has held it in 30 quarters since.
Vestmark Advisory Solutions's GSK position peaked at $5.88M in Q4 2025.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.